Senator Rand Paul (R-KY) has introduced a bill aimed at increasing transparency in financial transactions between the National Institutes of Health (NIH) and Big Pharma. The proposed legislation, known as the Royalty Transparency Act, seeks to mandate federal employees to disclose any royalty profits earned from new technological advancements. This move, as highlighted by @RandPaul, comes in response to concerns over the billions of dollars exchanged between the NIH and pharmaceutical companies, which Paul argues have been largely unscrutinized. The bill aims to address what is perceived as a lack of oversight in the financial dealings between these entities.